Tirzepatide·Eli Lilly·Injectable pen

Mounjaro

Mounjaro® is an FDA-approved once-weekly injectable tirzepatide pen manufactured by Eli Lilly, FDA-approved in May 2022 for the treatment of type 2 diabetes. Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. Mounjaro® is not FDA-approved for weight loss; the FDA-approved tirzepatide product for chronic weight management is Zepbound®. Weight Method does not dispense or prescribe brand-name Mounjaro®. Our prescribing providers issue patient-specific prescriptions for compounded tirzepatide, dispensed by U.S.-licensed 503A compounding pharmacies. Compounded tirzepatide is not FDA-approved.

2.5mg5mg7.5mg10mg12.5mg15mgOnce weekly
Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Mounjaro is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated June 2026Medically reviewed by licensed providers

Mounjaro (tirzepatide) is an FDA-approved GLP-1 medication for weight loss; in trials of the brand-name product, patients lost an average of 15-22% of their body weight. Weight Method does not dispense brand-name Mounjaro — it offers compounded tirzepatide, prescribed by licensed providers, from $199/month with virtual consultations and direct shipping.

Key Fact

Mounjaro (tirzepatide) is the first dual GIP/GLP-1 receptor agonist, FDA-approved for type 2 diabetes in May 2022. It is administered once weekly across a 2.5mg to 15mg dose range.

Source: FDA approval data — Mounjaro® prescribing information

How does this medication work?

Mounjaro (tirzepatide) is the first dual GIP/GLP-1 receptor agonist — targeting two metabolic hormones simultaneously to suppress appetite, boost fat metabolism, and improve insulin response.

Mounjaro works through a first-in-class dual-agonist mechanism, simultaneously activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. While GLP-1 activation suppresses appetite and slows gastric emptying -- similar to semaglutide -- the addition of GIP receptor activation enhances fat metabolism, improves how the body processes and stores energy, and amplifies insulin secretion from the pancreas. This two-pronged hormonal approach addresses weight and blood sugar from multiple biological pathways, distinguishing tirzepatide's mechanism from single-receptor GLP-1 medications like Ozempic or Wegovy.

What is it FDA-approved for?

FDA-approved for type 2 diabetes (2022), widely prescribed off-label for weight loss. Zepbound is the weight-specific brand of the same tirzepatide molecule.

Mounjaro is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. While Mounjaro does not currently carry a formal FDA indication for weight management (that indication belongs to its sister product Zepbound), physicians frequently prescribe Mounjaro off-label for weight loss given its exceptional clinical trial data. The SURPASS trial program demonstrated significant A1C reductions alongside weight loss in patients with type 2 diabetes, making Mounjaro an option for patients with type 2 diabetes who also need to lose weight.

What are the key facts you should know?

Once-weekly injection, 2.5mg to 15mg dose range, first-in-class dual agonist, FDA-approved for type 2 diabetes, manufactured by Eli Lilly.

Mounjaro is available in six dose strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, administered once weekly via a pre-filled injectable pen. It is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro was the first medication in its class and remains the only approved dual GIP/GLP-1 agonist for type 2 diabetes. It is manufactured by Eli Lilly at facilities in the United States and has been available since mid-2022.

Why choose this treatment?

Mounjaro's dual-hormone mechanism activates both GIP and GLP-1 receptors, a distinct approach from single-receptor GLP-1 drugs, and is FDA-approved for type 2 diabetes.

Mounjaro® has the FDA-approved indication for type 2 diabetes (May 2022) and was the first dual GIP/GLP-1 receptor agonist to reach the U.S. market. The SURPASS clinical-trial program of brand-name Mounjaro® demonstrated A1C reductions and weight loss in patients with type 2 diabetes; those outcomes were generated using the FDA-approved reference product. Patients seeking the FDA-approved brand-name Mounjaro® obtain it through a retail pharmacy. Weight Method does not dispense or prescribe brand-name Mounjaro®. For patients who, after consultation with a Weight Method provider, choose compounded tirzepatide as part of a chronic-weight-management program, Weight Method dispenses compounded tirzepatide through U.S.-licensed 503A compounding pharmacies at $329/month all-inclusive. Compounded tirzepatide is not FDA-approved.

Ready to Get Started?

Answer a few quick questions to see if you qualify.

Check Eligibility

Your Treatment Options

Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.

Starting at$199/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Compounded semaglutide. Once-weekly subcutaneous injection.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Compounded tirzepatide. Dual-action GLP-1/GIP, once-weekly subcutaneous injection.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors, while Ozempic contains semaglutide, which activates only GLP-1 receptors. The two medications work through different pharmacological mechanisms. Mounjaro is also dosed differently, starting at 2.5mg with a maximum of 15mg. Your Weight Method provider will determine the appropriate compounded medication and dosing for your goals.

While Mounjaro is FDA-approved specifically for type 2 diabetes, licensed providers can prescribe it off-label for weight management in eligible patients. Alternatively, Zepbound -- which contains the same tirzepatide molecule -- is FDA-approved specifically for weight loss. Your Weight Method provider will determine which tirzepatide formulation is most appropriate for your situation.

The most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. These typically occur during the initial weeks and after dose increases, and they generally improve as your body adjusts. The gradual dose-escalation schedule -- starting at 2.5mg and increasing every 4 weeks -- is designed to minimize these effects.

Mounjaro is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and its dual GIP/GLP-1 mechanism also reduces appetite. Individual outcomes vary and depend on dose, adherence, and lifestyle factors. Your Weight Method provider will set expectations for your individualized compounded tirzepatide plan during your consultation.

No. Weight Method does not dispense or prescribe brand-name Mounjaro®. Our prescribing providers issue patient-specific prescriptions for compounded tirzepatide, dispensed by U.S.-licensed 503A compounding pharmacies. Weight Method's compounded tirzepatide program is $329/month all-inclusive (medication, licensed-provider evaluation, ongoing provider access, dose management, and home shipping). Compounded tirzepatide is not FDA-approved.

Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide activates only the GLP-1 receptor — two different pharmacological mechanisms. Which medication is appropriate depends on your individual health profile, goals, and tolerability. Some patients respond well to semaglutide and others to tirzepatide. Your Weight Method provider will recommend the compounded medication best suited to your needs.

Most patients notice reduced appetite and early weight loss within the first 2-4 weeks of treatment. Clinically significant weight loss typically becomes visible by weeks 8-12 as the dose escalates. The full effect is generally observed after 6-12 months of consistent use at your maintenance dose. Your Weight Method provider monitors your progress throughout and adjusts your plan accordingly.

Start Your Treatment

Speak with a licensed provider today and find out if GLP-1 medications are right for you.

Get Started Now

Free consultation. No commitment.

More about Mounjaro

Mounjaro Side EffectsMounjaro ResultsMounjaro Dosingtirzepatide Dosage Calculator

Generic Medication

Tirzepatide

Other Tirzepatide Brands

ZepboundTirzepatide

Compare Mounjaro

Mounjaro vs ZepboundOzempic vs MounjaroWegovy vs Mounjaro

Mounjaro by State

Mounjaro in AlabamaMounjaro in AlaskaMounjaro in ArizonaMounjaro in ArkansasMounjaro in CaliforniaMounjaro in Colorado